Precigen Stock Has To Grow Into Its Valuation (NASDAQ:PGEN)

seekingalpha.com · 2026-08-08

Precigen (PGEN) jumped on PAPZIMEOS FDA approval, but a premium valuation and single-drug reliance hurt risk/reward. See more details here.